This CME program, derived from content presented at the Advanced Curriculum for Multiple Sclerosis 2020 Course in West Palm Beach, Florida, will highlight novel treatment strategies to improve outcomes in patients with relapsing remitting multiple sclerosis (RRMS). The expert faculty will review the science of relapsing remitting multiple sclerosis, including risk mitigation and the pharmacokinetics of current therapeutic options. Safety, efficacy and tolerability data for novel therapeutic options for the treatment of RRMS will also be discussed. The faculty will review how to utilize individualized treatment strategies to effectively reduce the rate of multiple sclerosis relapses and slow the progression of disability in MS patients.
Neurologists and other healthcare professionals who care for patients with MS
I. Relapsing Remitting Multiple Sclerosis: The Importance of Risk Mitigation & the Pharmacokinetics of Novel Therapeutic Options
II. The Safety, Efficacy, and Tolerability Data for Novel Therapeutic Options for the Treatment of RRMS
III. Utilize individualized treatment strategies to more effectively reduce the rate of MS relapses and slow the progression of disability
- Understand the science of relapsing remitting multiple sclerosis, including risk mitigation and the pharmacokinetics of novel therapeutic options
- Review the safety, efficacy, and tolerability data for novel therapeutic options for the treatment of RRMS
- Utilize individualized treatment strategies to more effectively reduce the rate of MS relapses and slow the progression of disability
Stephen Krieger, MD
Associate Professor of Neurology
Icahn School of Medicine at Mount Sinai
Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, New York
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
Fred D. Lublin, MD
|Consultant/Advisor: Actelion Pharmaceuticals; Apitope; Atara Biotherapeutics; Biogen; Brainstorm Cell Therapeutics; EMD Serono, Inc.; GW Pharmaceuticals; Innate Immunotherapeutics; Jazz Pharmaceuticals; MedDay Pharmaceuticals; Mapi Pharma; MedImmune, LLC/Viela Bio; Novartis Pharmaceuticals Corporation; Orion Biotechnology; Polpharma Group; Population Council; Receptos, Inc./Celgene Corporation; Roche Group/Genentech Inc.; Sanofi Genzyme; Teva Pharmaceuticals; TG Therapeutics, Inc.
Grant/Research Support: Novartis International AG; Actelion Pharmaceuticals; Biogen Inc.; Sanofi U.S.; NMSS; NIH; Brainstorm Cell Therapeutics
Speaker’s Bureau: Sanofi U.S.
Mark S. Freedman, MSc, MD
|Consultant/Advisor: Actelion Pharmaceuticals; Alexion Pharmaceuticals; Atara Biotherapeutics; Bayer Healthcare; Biogen; Clene Nanomedicine, Inc.; EMD Serono, Inc.; EMD Serono, Inc. (Canada); Hoffman La-Roche; Janssen; MedDay Pharmaceuticals
Grant/Research Support: EMD Serono, Inc.; Sanofi-Genzyme Canada Pharmaceuticals; Novartis Pharmaceuticals; Sanofi Genzyme; Celgene Corporation (BMS); Chugai; Teva Canada Innovation
Speaker’s Bureau: EMD Serono, Inc.; Sanofi-Genzyme
Stephen Krieger, MD
|Consultant/Advisor: Biogen; EMD Serono; Genentech Inc.; Genzyme; Mallinckrodt Pharmaceuticals; MedDay Pharmaceuticals; Novartis International AG; Teva Pharmaceutical Industries Ltd.; TG Therapeutics
Speakers Bureau: Biogen Inc.; EMD Serono, Inc.; Genentech Inc.; Novartis International AG
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
This activity has been supported by an independent educational grant from Biogen
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].